Have you ever wondered what's like to be face to face with bed. Hello everyone, my name is Jane 2. Today I'll be sharing my cancer story with you guys.At the age of 16, I was diagnosed with life 30 cancer. It feels almost unreal to this day. Whenever I tell this story, it feels like I'm talking about some other person's story.Exactly one year ago, I was halfway through my chemo and I was questioning every single meaning of my life. Will I ever make it. I thought it was an ordinary child when I first arrived ...

DNase I Oncology Platform - The company is focused on advancing its proprietary DNase I technology platform to address multiple high-value cancer indications[2, 5] - DNase I targets Neutrophil Extracellular Traps (NETs) to improve immunotherapies and chemotherapies[2, 5] - DNase I digests both double and single-stranded DNA, as well as DNA:RNA hybrids, exposing cancer cells to the immune system and reducing therapy resistance[6] - Systemic administration of DNase I improves the efficacy of PD-1 blockade, resulting in the lowest tumor volume growth compared to either DNase I or anti-PD-1 alone[19] Pipeline and Clinical Development - The company's lead program, XBIO-015, combines systemic DNase I with chemotherapy for pancreatic carcinoma[7] - A Phase 1 study is planned, featuring dose escalation and expansion in subjects with locally advanced or metastatic solid tumors, with pancreatic cancer and other solid tumor indications[2, 40] - The company believes that an ORR greater than 50% or PFS greater than 9 months would be a meaningful improvement to the current standard of care for pancreatic cancer[45] Market Opportunity - The company is initially targeting pancreatic carcinoma, a multi-billion-dollar indication with significant unmet need, with a projected market of $48 billion by 2025[2, 39] - Approximately 62,000 people are diagnosed with pancreatic cancer annually, and approximately 50,000 die from it annually[39] - There were approximately 19 million new solid tumor cases in the U S in 2022, leading to approximately 6 million solid tumor-related deaths[46] Collaboration and Intellectual Property - The company is collaborating with VolitionRX to develop proprietary adoptive cell therapies potentially targeting multiple solid cancer types[2, 58] - VolitionRX is expected to fund the research program, with both parties sharing proceeds from commercialization or licensing of any resulting products[60] - The company has an IP portfolio covering the co-administration of Systemic DNase I with ICIs, radiation, and chemo, as well as DNase I for pancreatic cancer and DNase I-secreting CAR T cells[62, 64]

There are moments which mark your life. Moments when you realize nothing will ever be the same. And time is divided into two parts.Before this and after this. Sometimes you can feel such a moment coming. And that's the test.Or so I tell myself. I tell myself that at times like that, strong people keep moving forward anyway, no matter what they're going to find. Hi, I've been told that there's a handful of you here who were told that I was going to be giving a speech about the most expensive haircut I ever r ...